uniQure (NASDAQ:QURE) Raised to Sell at StockNews.com

StockNews.com upgraded shares of uniQure (NASDAQ:QURE) to a sell rating in a research note released on Thursday morning.

A number of other equities analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a report on Tuesday, August 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 target price on shares of uniQure in a research note on Friday, September 20th. Raymond James reissued an “outperform” rating and set a $20.00 price target on shares of uniQure in a research note on Thursday, October 10th. Finally, The Goldman Sachs Group upped their price objective on shares of uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $19.50.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $6.28 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.36 and a quick ratio of 7.36. The business has a 50-day moving average of $5.78 and a 200-day moving average of $5.65. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.08. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%. The business had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $3.47 million. As a group, sell-side analysts expect that uniQure will post -4.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in QURE. Vanguard Personalized Indexing Management LLC grew its holdings in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares during the last quarter. Total Clarity Wealth Management Inc. purchased a new stake in shares of uniQure during the second quarter worth about $74,000. SG Americas Securities LLC bought a new stake in shares of uniQure in the second quarter worth about $79,000. Cubist Systematic Strategies LLC increased its holdings in uniQure by 130.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 14,454 shares during the period. Finally, Doheny Asset Management CA bought a new position in uniQure during the 2nd quarter valued at approximately $1,220,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.